Exercise of Options, Director Dealings & TVR

About this update from Venture Life Group Plc

2 January 2026   VENTURE LIFE GROUP PLC ("Venture Life", "VLG" or the "Group") Exercise of Options, Director Dealings and Total Voting Rights   Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy, product innovation, development, and commercialisation within the global consumer healthcare sector, announces that on 31 December 2025 it issued 483,333 new ordinary shares of 0.3 pence each in the capital of the Company (" Ordinary Shares ") following an exercise of options by Jerry Randall, Chief Executive Officer of the Company, pursuant to the Company's Long-Term Incentive Plan (" LTIP "). The options were exercised at a price of 41.0 pence per Ordinary Share and were due to expire on 31 December 2025. Following the option exercise, Jerry Randall beneficially holds 2,736,533 Ordinary Shares representing approximately 2.13 per cent. of the Company's issued share capital. Application will be made to the London Stock Exchange for 483,333 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective, and trading will commence at 8.00 a.m. on 7 January 2025. Assuming no further repurchases of Ordinary Shares pursuant to the Company's buyback programme announced on 30 September 2025 prior to Admission, the total number of Ordinary Shares in issue on Admission will be 128,737,145, with 1,739,981 Ordinary Shares held in treasury. Therefore, the total number of voting rights will be 126,997,164. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.   For further information, please contact: Venture Life Group PLC                                                                                                    +44 (0) 1344 578004 Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer   Cavendish Capital Markets Limited (Nomad and Broker)                           +44 (0) 20 7720 0500  Stephen Keys/George Lawson (Corporate Finance) Michael Johnson (Sales)    About Venture Life ( www.venture-life.com ) Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK,  Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.    The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation: 1   Details of the person discharging managerial responsibilities / person closely associated   a)   Name   Jerry Randall 2   Reason for the notification   a)   Position/status   Chief Executive Officer b)   Initial notification /Amendment   Initial notification 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor   a)   Name   Venture Life Group plc b)   LEI   213800S8CZUPLAB2KC70 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted   a)   Description of the financial instrument, type of instrument     Identification code   Ordinary Shares of 0.3p each in Venture Life Group plc       GB00BFPM8908 b)   Nature of the transaction   Exercise of share options c)   Price(s) and volume(s)       Price Volume 41.0 pence 483,333 d)   Aggregated information   - Aggregated volume   - Price   N/A - Single transaction             e)   Date of the transaction   31 December 2025 f)   Place of the transaction   Outside of a trading venue          

View stock analysis, news, and events for Venture Life Group Plc